

 **Tecfidera**<sup>®</sup>  
(dimethyl fumarate)



\*THIS INCLUDES CLINICAL TRIAL USE AND PATIENTS PRESCRIBED TECFIDERA.

FOR THE TREATMENT OF ADULT  
PATIENTS WITH RRMS

***START EARLY.  
STAY IN CONTROL.***

TECFIDERA effectively impacts disease  
activity in the long term.<sup>1-5</sup>



 **Biogen.**

Biogen-131285 | January 2022

**References:**

1. TECFIDERA SmPC; please refer to the approved SmPC in your country. 2. Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. *J Neurol.* 2017;264(12):2351-2374. 3. Gold R, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. *Mult Scler.* 2017;23(2):253-265. 4. Gold R, et al. Sustained effect of delayed-release dimethyl fumarate in newly diagnosed patients with relapsing-remitting multiple sclerosis: 6-year interim results from an extension of the DEFINE and CONFIRM studies. *Neurol Ther.* 2016;5:45-57. 5. Tecfidera Exposure Data 4 March 2021. Biogen Data on File.